Pharmacokinetic parameters, such as the area under the concentration-time curve (AUC) from 0 to infinity after the administration of luseogliflozin, are similar regardless of the degree of renal impairment in patients with type 2 diabetes [31], although the AUCs of other SGLT2 inhibitors are increased in patients with renal impairment [47, 48]. Here, SLC5A2 is linked to type 2 diabetes mellitus.